No short-lived results
Common (mild, transient): Injection site reactions mild erythema, swelling, itching, or discomfort, reported in ~15-25% of users
Regulatory status: BPC-157 is not an approved human medicinal product in any regulatory zone (FDA, EMA, KL)
This method allows for rapid absorption and distribution of vitamins, minerals, and other compounds throughout the body
"Placebo-controlled" means the control group receives an identical-looking but inactive product, so any improvement in the treatment group can be attributed to the active ingredients rather than the act of applying something
Additionally, NBDHEX treatment has led to elevated caspase-dependent apoptosis in various cancer cells, including leukemia cells expressing MDR1